By E. Temmy. Texas A&M University, Kingsville. 2019.
Effective against HBV discount vantin 100mg fast delivery, beware of viral rebounds after discontinuing FTC order generic vantin. For detailed information see page: 74 Emtriva generic 100mg vantin with visa, see Emtricitabine purchase line vantin. Ethambutol Manufacturer: among others Riemser Several generics. Indications and trade names: tuberculosis, MAC infection. It is usually reversible if ethambutol is discontinued immediately. Other side effects: nausea, vomiting, abdominal pain, headache, dizziness, pruritus, arthralgia, elevated serum uric acid (possible acute gout attacks), abnormal liver function tests. Interactions, warnings: ethambutol is contraindicated with pre-existing optical nerve damage. Ophthalmologic examination before initiation of treatment and subsequently at 4-week intervals (color discrimination, field of vision, acuity). Immediate discontinuation to prevent optical atrophy if vision impairment occurs. Patients should be informed that impairment of vision may occur and to immedi- ately report this to the treating physician. Aluminum hydroxide reduces absorption of ethambutol; ethambutol should therefore be taken at least one hour before antacids. Monitor liver values and uric acid levels at monthly intervals. Indications and trade name: in combination with a boosted PI and other anti- retroviral agents for the treatment of HIV-1 infection in antiretroviral treatment- experienced adult patients and in children aged 6 years or older. With mild exanthema, which usually appears in the second week, treatment can usually be continued, immediately stop- ping at a serious exanthema. In October 2009, the company published a Dear Doctor letter, reporting on three cases of TEN. Interactions, warnings: etravirine is a substrate of the CYP450 enzyme system as well as an inducer of CYP3A4 and an inhibitor of CYP2C9, therefore, some interac- tions are to be anticipated. Etravirine reduces the serum concentrations of atazanavir, maraviroc and raltegravir and increases fosamprenavir levels. On the other hand, etravirine levels are considerably reduced by tipranavir, efavirenz and nevirapine (moderately by darunavir, saquinavir and tenofovir). Lopinavir and delavirdine increase the levels of etravirine. Etravirine should not be combined with the following: atazanavir, fosamprenavir, tipranavir, unboosted PIs or other NNRTIs. Avoid rifampicin, carbamazepine, phe- nobarbital, phenytoin and St. Drug Profiles 695 Comments: etravirine is the first second-generation NNRTI that was licensed in 2008 for pre-treated patients. It is well-tolerated and effective against some (but not all) NNRTI-resistant HIV strains. Should be combined with a boosted PI (preferably darunavir, due to the lack of data with other PIs). For detailed information see page: 84 Eviplera, see Complera. Evotaz, see Atazanavir and Cobicistat Exviera, see Dasabuvir. Fluconazole Manufacturers and trade names: Pfizer and many other companies, therefore several trade names, such as Diflucan, Fluconazole CT/Stada, or Flucobeta. Indications: Candida infection, cryptococcal meningitis and some rare mycoses. Suspension, 50 mg per 10 ml • Fluconazole IV for injections, 100, 200 and 400 mg Dosage: for oral candidiasis, 100 mg QD orally; for candida esophagitis 200 mg QD for 7–10 days. An attempt with a higher dose (up to 800 mg daily) may be made if there is persistent candidiasis after 10 days. Cryptococcal meningitis: Acute therapy for 6 weeks with 400–800 mg daily, com- bined with flucytosine and amphotericin B if possible. Then maintenance therapy with 200 mg fluconazole daily. Renal insufficiency: half the dose with creatinine clearance of 10 to 50 ml/min; reduce to 25% below 10 ml/min. Side effects: Rarely gastrointestinal complaints and elevated transaminases. Reversible alopecia in approximately 10% of cases with more than 400 mg daily. Interactions, warnings: long-term treatment may lead to development of candida- resistant strains. Fluconazole levels are reduced with concurrent administration of rifabutin/rifampin. Fluconazole increases the serum levels of rifabutin, atovaquone, clarithromycin, theophylline, opiates, coumarin derivatives, benzodiazepines, cyclosporine, tacrolimus, phenytoin and anti-convulsive drugs as well as AZT. Comments: fluconazole is the first choice for HIV-associated candidiasis and for the secondary prophylaxis of cryptococcosis (also as component of acute therapy). Infusions (more expensive) are only required in cases of non-adherence, severe mucositis, and/or problems with absorption. Indications and trade names: HIV infection, for both treatment-naïve and experi- enced patients (for limitations, see below). Suspension, 50 mg/ml (225 ml bottle) Dosage in treatment-naïve patients: 700 mg BID + 100 mg ritonavir BID (2 x 2 pills, normal dose) 1400 mg BID (without ritonavir, not approved in Europe) 1400 mg QD + 200 mg ritonavir QD (1 x 4 pills; not approved in Europe) Dosage in PI-experienced patients: 700 mg BID + 100 mg ritonavir BID (2 x 2 pills) Side effects: most frequently diarrhea, may be severe in some cases. Interactions, warnings: Fosamprenavir can be taken on an empty stomach or with a meal. Contraindicated: cisapride, midazolam, ergotamines, flecainide and propafenone. There may be life-threatening interactions upon concurrent adminis- tration of amiodarone, lidocaine (systemic), tricyclic anti-depressants and quinidine. Do not use together with rifampin, delavirdine or St. John’s wort; use cautiously with simvastatin, lovastatin, sildenafil, vardenafil. Carbamazepine, phenobarbital, and phenytoin can lower plasma levels of amprenavir. Rifabutin: dose reduction of rifabutin by at least 50%. If fosamprenavir is boosted with ritonavir, a 75% reduction of the rifabutin dose is required (instead of 300 mg daily, only 150 mg every other day, or 150 mg three times per week). Efavirenz seems to lower plasma levels significantly (probably clinically relevant). However, this is not the case if fosamprenavir is boosted with ritonavir. If fosam- prenavir/r is administered once daily, then the ritonavir dose should be increased to 300 mg. Caution in combination with lopinavir – plasma levels of both drugs are reduced. If fosamprenavir is boosted with ritonavir, ketoconazole and itraconazole maximum dose 200 mg daily. Caution in patients with sulfonamide allergy or with reduced liver function. Comments: Except for diarrhea, this PI is well-tolerated. However, fosamprenavir currently does not play an important role in HIV medicine. One advantage of the drug is that there are no restrictions with respect to food intake. For detailed information see page: 94 Foscarnet Manufacturer: AstraZeneca. Indications and trade name: reserve drug for induction and maintenance therapy of CMV retinitis. Severe acyclovir-resistant herpes or varicella zoster infections.
The other two studies compared medications from different groups i generic vantin 200 mg without a prescription. In clinical practice vantin 200mg free shipping, these medications are often used together since they work in different ways to improve bowel movements buy discount vantin 100 mg on-line. For comparative safety in adults 43 we found four head-to-head trials comparing PEG 3350 with lactulose vantin 200 mg on line, lactulose with psyllium (2 65, 66 45 trials), and PEG 3350 with psyllium. All four of these studies had severe methodological limitations and were rated as poor quality for assessment of adverse events and no firm conclusions can be drawn about the comparative safety of these drugs. For pediatric populations, the evidence for general efficacy and safety is very poor quality and sparse. We found no studies on the general efficacy, tolerability, or safety of docusate calcium, docusate sodium, lactulose, lubiprostone, and psyllium that met our eligibility criteria. All of the studies we found were rated poor quality and results should be interpreted with caution. For comparative evidence of general efficacy and safety in pediatric populations, we found just one head- 46 to-head trial comparing PEG 3350 with lactulose. However, this study was of poor quality due to methodological limitations. The results should be interpreted cautiously due to the poor quality of the evidence. Constipation Drugs Page 69 of 141 Final Report Drug Effectiveness Review Project Likewise, no evidence is available to determine the ideal treatment duration of drugs used to treat chronic constipation or when treatments should be switched if patients do not respond. Similarly, we did not find any studies published as full text articles specifically designed to compare the effect of constipation drugs in particular subpopulations. The lack of scientific evidence for drugs used to treat constipation has been pointed out in several 71, 73-75 systematic reviews. Some of these studies focused on interventions not included in this report; others examined the efficacy and safety in populations with occasional constipation. All of them stress the lack of high quality evidence to support the efficacy and safety of most interventions. Nevertheless, the absence of evidence of an effect cannot be interpreted as evidence of no effect. Therefore, it is important that well conducted future studies reliably establish the efficacy of all commonly used medications used for treatment of constipation. Furthermore, the comparative efficacy and effectiveness of first-line over-the-counter treatments and first-line prescription treatments have to be compared. Moreover, it is important to examine whether new second-line treatments, such as lubiprostone, have an additional, clinically significant treatment benefit as well as better tolerability and safety compared with other available interventions. In addition, it is important that these studies will investigate the effects of these interventions on a variety of constipation related symptoms including straining, bloating, and abdominal discomfort as well as on the patients’ overall well-being and quality of life. Finally, future research should more fully assess comprehensive safety and tolerability data, because much of the current literature does not adequately address these issues. This data will provide clinicians with helpful information needed for better selection of appropriate intervention for patients with chronic functional constipation. Constipation Drugs Page 70 of 141 Final Report Drug Effectiveness Review Project Table 33. Summary of the evidence by key question Indication Strength of the Conclusion Evidence Key Question 1a: General Efficacy Chronic Moderate Consistent evidence of three studies with mixed methodological constipation in quality supports the efficacy of PEG 3350 for the treatment of adults chronic constipation. Low Two studies of mixed quality support the efficacy of psyllium for the treatment of chronic constipation. High Multiple well conducted studies provide evidence of the efficacy of tegaserod for the treatment of chronic constipation. However, because of safety concerns, tegaserod is currently not available in the US. Studies of lubiprostone have been published as abstracts only. No evidence is available on docusate calcium, docusate sodium, and lactulose. Chronic No evidence constipation in children IBS-C in adults High Multiple, well conducted studies provide evidence of the efficacy of tegaserod for the treatment of IBS-C in adults. However, because of safety concerns, tegaserod is currently not available in the US. N/A Studies of lubiprostone have been published as abstracts only and available information is insufficient to critically appraise the methods and draw firm conclusions. N/A No evidence is available on docusate calcium, docusate sodium, lactulose, PEG 3350, and psyllium for the treatment of IBS-C in adults. IBS-C in children Low One RCT provided evidence of the efficacy of tegaserod for the treatment of IBS-C in adolescents, particularly in reduction in pain. However, because of safety concerns, tegaserod is currently not available in the US. N/A No evidence is available on docusate calcium, docusate sodium, lactulose, PEG 3350, and psyllium for the treatment of IBS-C in children. Key Question 1b: Comparative Efficacy Chronic Low Docusate sodium vs. PEG 3350: One poor quality RCT reported fewer weekly stools and less overall improvement for lactulose than PEG 3350 Low PEG 3350 vs. IBS-C in adults No evidence IBS-C in children No evidence Key Question 2: Treatment duration No evidence Key Question 3: General Safety Chronic Low One fair and 2 poor quality studies reported that PEG 3350 was well constipation or tolerated with only minor gastrointestinal adverse events. IBS-C in adults Low Three poor quality studies consistently reported that psyllium was well tolerated with no difference in adverse events from placebo. High Multiple well conducted studies provide consistent evidence of an increased incidence of diarrhea with tegaserod compared with placebo. Due to an increased risk of cardiovascular events tegaserod was taken off of the market in March 2007. N/A Studies of lubiprostone have been published as abstracts only. N/A No evidence is available on docusate calcium, docusate sodium, and lactulose. Chronic Low The most common adverse events reported in 3 poor quality studies constipation or of PEG 3350 without comparison groups were diarrhea (10-13%), IBS-C in children bloating/flatulence (6-18%), and pain/cramping (2-5%). No significant laboratory abnormalities were reported. Low One RCT reported no adverse events were observed in any patient and there were no dropouts for postpubertal adolescents with IBS-C treated with tegaserod. N/A No evidence is available on docusate calcium, docusate sodium, lactulose, lubiprostone, and psyllium Key Question 3: Comparative Safety Chronic Low Lactulose vs. PEG 3350: constipation or One poor quality RCT reported lower rates of flatus and abdominal IBS-C in adults pain, but higher rates of diarrhea for PEG. PEG 3350: constipation or Two poor quality studies provided mixed evidence about differences IBS-C in children of adverse events between lactulose and psyllium. Key Question 4: Subgroups Efficacy and Chronic constipation: harms based on N/A One pooled data analysis of lubiprostone published as an abstract sex only. N/A No evidence is available on docusate calcium, docusate sodium, lactulose, PEG 3350, psyllium or tegaserod. Constipation associated with IBS: N/A No evidence is available on docusate calcium, docusate sodium, lactulose, lubiprostone, PEG 3350, psyllium or tegaserod. Efficacy and Chronic constipation: harms based on N/A Two pooled data analyses of lubiprostone in patients > 65 years age published as abstracts only. N/A No evidence is available on docusate calcium, docusate sodium, lactulose, PEG 3350, psyllium or tegaserod. Constipation associated with IBS: N/A No evidence Efficacy and No evidence harms based on race/ethnicity Efficacy and No evidence harms based on co-morbidities Constipation Drugs Page 73 of 141 Final Report Drug Effectiveness Review Project ADDENDUM 76 As this report was going to press, the first full text study on lubiprostone was published. In this RCT, 129 patients with chronic constipation were randomized to lubiprostone (24, 48, or 72 mcg/day) or placebo. During the 21 days of follow-up, lubiprostone improved spontaneous bowel movement (SBM) rates in a dose-dependent manner. The most common adverse events were nausea (33%), headache (11%), and diarrhea (11%).
However 100 mg vantin sale, it is fair to state that existing formal bleeding risk scores predict major bleeding Warfarin management in patients with VTE only modestly well purchase 100mg vantin free shipping. Finally buy vantin toronto, patient treatment preference needs tered clinical issues are provided in a 2014 ASH Quick Reference to be taken into consideration (see “Patient preference or ‘warfarin Guide on antithrombotic therapy order vantin 100 mg without prescription, adapted in part from the ACCP hate factor’: the author’s approach” section below). VTE recurrence prediction models to moderately symptomatic DVT without risk factors for DVT Several models or scoring systems have been developed in an extension (eg, no continued immobility or cancer), serial fol- attempt to predict recurrent VTE and make the translation of low-up ultrasounds rather than anticoagulation are recom- existing guidelines into clinical practice easier: the HERDOO-2 mended. For distal DVT that is asymptomatic or with nonsevere score,49 the DASH score,50 and the Vienna model. I use a “Warfarin Hate Factor” or, now that the simple web-based VTE recurrence risk calculator has been devel- 53 NOACs are in clinical use, a “Blood Thinner Hate Factor” scale for oped based on the Vienna model. I ask the patient to give me a number on a scale scores/models for solid clinical decision making, but I do use the from 0 to 10 how much he/she “hates” being on warfarin, taking into HERDOO-2 score and DASH score for curiosity’s sake in patients consideration the following: INR ﬂuctuations, the inconvenience of whom I assess as having an intermediate risk of recurrence (Figure the need for monitoring, dietary restrictions, fear of major bleeding 2) to see whether both scores come to the same conclusion as to or recurrent clot, impact of the anticoagulant on his/her lifestyle, and whether to stop or continue anticoagulation. A “hate factor” of “zero” 1,22,23 reﬂects: “I don’t mind at all being on warfarin—it’s just a pill I Length of anticoagulation based on ACCP 2012 take”; “10” means: “I hate warfarin so much, I need to come off; I don’t care about another clot. In patients whose ﬁrst proximal often opens up the discussion on the burden of being on an DVT or PE event was associated with surgical or nonsurgical anticoagulant. It provides me as the physician with the patient transient VTE risk factor (hospitalization, immobility, cast immobi- value/preference perspective needed for decision making on length lization, contraceptives), 3 months of anticoagulation are of anticoagulation (Figure 1). Long-term anticoagulation is recommended in such patients if they have no bleeding problems or risk factors and tolerate warfarin “Risk of recurrence triangle”: the author’s approach to well. First I draw for the patient the “recurrence recurrence, but not strongly or consistently enough to inﬂuence triangle” (Figure 2), marking where approximately in the triangle recommendations on duration of therapy once the primary factors the patient falls regarding his/her risk of recurrent VTE. I use the (VTE due to transient risk factor vs unprovoked event, presence of ACCP 2012 guidelines1 as the major evidence-based building block cancer) and secondary factors (proximal vs distal DVT; was this a for this triangle, concluding the following. First, a patient with VTE ﬁrst VTE event or recurrent episode? For patients with cancer and DVT or PE, of the triangle. Second, patients with unprovoked VTE have a LMWH for 3-6 months is recommended; thereafter, LMWH or higher risk of recurrence and fall in the lower part (the base) of the warfarin with a target INR of 2-3 indeﬁnitely or until the cancer has triangle. Based on conglomerate published data, men with unpro- resolved. For severely symptomatic distal DVT, anticoagula- associated VTE are still in the lower part of the triangle but are tion for 3 months is recommended. Thrombophilia tests to consider when testing is indicated: pregnancy, minor surgery, minor immobility such as long-distance the author’s approach travel) appear to have an intermediate risk of recurrence and CBC therefore fall in the middle area of the triangle. Protein C activity Protein S activity, free protein S A positive D-dimer or the presence of a strong thrombophilia in the Antithrombin activity intermediate-risk patient leads me to move the patient downward, Anticardiolipin IgG and IgM antibodies further toward the broad base of the triangle, indicating a higher risk Anti-ß2-glycoprotein-I IgG and IgM antibodies recurrence. Presence of a mild thrombophilia (eg, heterozygous Lupus anticoagulant JAK2 V617F and ﬂow cytometry for PNH in splanchnic vein thrombosis factor V Leiden, heterozygous prothrombin G20210A mutation) Flow cytometry testing for PNH if unexplained cytopenias present does not change or only slightly changes the position of the patient downward in the triangle because the heterozygous prothrombin G20210A mutation is not a risk factor for recurrent VTE and the heterozygous factor V Leiden mutation is only a mild risk factor for deﬁciency, (6) antithrombin deﬁciency, and (7) antiphospholipid recurrence. The tests I would consider, if testing is indicated, are listed in Table 4. The horizontal dashed line (Figure 2) indicates the approximate risk above which short-term anticoagulation (3 months) seems appropri- Aspirin to prevent VTE recurrence ate. Scientiﬁcally, it is the position above which the case fatality Aspirin appears to have some, although only a modest, beneﬁcial from recurrent VTE is lower than the one from bleeding on warfarin 58 effect on decreasing the risk of recurrent VTE. However, case fatality from bleeding in patients trials, the WARFASA and ASPIRE trials, were published in 2013 on long-term warfarin for secondary VTE prevention, as well as in patients on the NOACs, is not accurately known. Similarly, in the patient with a not show a statistically signiﬁcant beneﬁt of aspirin, although a strong preference not to be on anticoagulation—that is, a patient trend toward beneﬁt (HR 0. Reasons for the somewhat discrepant ﬁndings—the marked beneﬁt of aspirin in the smaller WARFASA trial versus only a trend toward “Long-term” anticoagulation is also referred to as “extended” or, in beneﬁt in the larger ASPIRE trial—may be that patients at higher clinical practice terminology, as “indeﬁnite” or “life-long,” meaning risk for recurrent VTE were studied in the WARFASA trial, so it for years to come. However, periodic reevaluation is indicated with was easier to detect a beneﬁcial effect of aspirin in the smaller study new risk-beneﬁt assessment of anticoagulation, taking into consider- with higher-risk patients. The fact that the VTE recurrence rate in ation new clinical trial data, updates on the status of new anticoagu- the placebo arm was 11% per year in the WARFASA trial and only lants, and reassessment of a patient’s bleeding risk and treatment 6. Because the trial design of the studies was similar, a pooled analysis of both trials was Thrombophilia workup: the author’s approach 13,14 performed. It showed a statistically signiﬁcant beneﬁt of aspirin No full agreement exists as to who should be tested for thrombo- over placebo on the rate of recurrent VTE (HR 0. My conclusion with VTE associated with a major risk factor (ie, patients in the tip is that aspirin appears to have some beneﬁcial effect, but that it is of the recurrence triangle) should not undergo thrombophilia 6 modest at best, clearly less than the beneﬁt of continued anticoagu- testing. The ACCP 2012 guideline concludes that inherited throm- lation with warfarin or one of the NOACs. However, given that strong thrombophilias are risk factors for VTE recurrence,59,60 I consider thrombophilia testing in an option in the patient in whom anticoagulation is discontinued the patient who is in the intermediate risk of recurrence area of the because the risk of recurrence is considered to be low enough that recurrence triangle because ﬁnding a strong thrombophilia pushes long-term anticoagulation is not chosen or the patient has a high the patient down into the broader base of the triangle and is one anticoagulation hate factor. Although aspirin in the WARFASA and of the reasons to consider long-term anticoagulation. I consider 7 ASPIRE studies did not lead to an increased risk of major bleeding, thrombophilias as being “strong”: (1) homozygous factor V Leiden, it has, in other studies and patient populations, increased the risk for (2) homozygous prothrombin G20210A gene mutation (II20210), major bleeding. Choosing long-term aspirin should therefore always (3) double heterozygous state (heterozygous factor V Leiden PLUS be a judicious decision incorporating an individual patient’s risk heterozygous II20210), (4) protein C deﬁciency, (5) protein S factors for bleeding. The year 2013 saw the FDA approval of a new oral drug, Postthrombotic syndrome riociguat (Adempas), to treat pulmonary hypertension. A recent well-designed randomized, doubled-blinded guanylate cyclase stimulator that leads to arterial dilatation and study (the SOX trial) published in 2013 showed that compression improves exercise tolerance and is indicated for patients with stockings worn for 2 years after an episode of acute DVT did not 16 CTEPH after surgical pulmonary endarterectomy or those who prevent PTS. Therefore, one can conclude that patients do not cannot undergo surgery. Although 2 previous studies had shown that wearing elastic compression stockings decreased the risk of develop- ing PTS, these studies were limited by their small size and the fact Contraceptives and VTE that they were single-center trials. To further clarify whether It is well established that combination contraceptives (containing stockings do play any role in preventing PTS, a randomized study estrogens and progestins) increase the risk for VTE and that the type (IDEAL study; clinicialtrials. A 2012 systematic review and after an initial therapeutic period of 6 months, with elastic compres- meta-analysis of trials evaluating the VTE risk associated with sion therapy with a standard duration of 24 months. Although, with our current knowledge from the SOX only pills and VTE (relative risk 0. Therefore, a stocking should be offered to any patient with ately point out that the strength of the conclusions is limited by the bothersome leg symptoms. These should be graduated compression paucity of literature on the topic and suggest that until more data stockings with a compression pressure of 35 mmHg at the ankle and become available, noninjectable forms of progestin-only contracep- 25 mmHg at the midcalf, also sometimes referred to as “grade 2. This conclusion matches TED (thromboembolism-deterrent) stockings are not sufﬁciently my approach in the discussion with patients. However, it is tight because they deliver only 20 mmHg of pressure. A practical, worthwhile to point out that the analyzed studies have investigated comprehensive informational handout on stockings for patients the impact on progestin-contraceptives on a ﬁrst (ie, incident) VTE (what stocking is right for me? It is not known whether progestin-only contraceptives are online. I am only aware of one published pelvic MRI-venogram or CT-venogram should be considered to study of women with thrombosis or with a family history of thrombosis who took a progestin-only pill. In addition, use of a there was no increased risk of thrombosis with the progestin-only home compression pump worn on the extremity for 30-60 minutes pill. However, the progestin contraceptive evaluated in the study is once or twice daily may be beneﬁcial. The advice I presently give to a woman with known strong thrombo- Pulmonary hypertension philia or with a history of VTE, particularly when additional VTE risk The current deﬁnition for pulmonary hypertension (PH) is a mean factors (eg, obesity) are present, is to advise against the use of pulmonary artery pressure of 25 mmHg at rest by right heart injectable contraceptives (Depo-Provera, Implanon rod). I state that catheterization, with normal pulmonary wedge pressure. For the As a resource primarily for patients with VTE, but also for health patient with a history of large PE or signiﬁcant residual shortness of care professionals looking after such patients, comprehensive breath, fatigue, and exercise intolerance that does not improve information has been made available on the Clot Connect website further or deteriorates, the following screening for CTEPH is 63 (www. A recent publication in the (1) pulse oximetry at rest and after climbing stairs (or formal Circulation “Patient Page” can also be used as an educational 6-minute walk test in a pulmonary function laboratory); (2) cardiac handout for patients with VTE, addressing many of the questions echocardiogram with focus on right heart and estimation of that patients with VTE have. Off-label drug use: Edoxaban (by Daichi) Referral to a specialized PH clinic for objective documentation of is not FDA approved for VTE as of 9/25/2014; Daiichi has applied PH (ie, right heart catheterization) and coordination of possible for FDA approval for their drug; by the time of the manuscript Hematology 2014 303 completion and the ASH 2014 presentation, this drug may or may 16. Compression stockings to prevent not be FDA approved for VTE. Assessing the risk of venous Correspondence thromboembolic events in women taking progestin-only contraception: Stephan Moll, MD, Professor of Medicine, Division of Hematology- a meta-analysis. Oncology, Department of Medicine, University of North Carolina 18.
All included studies order genuine vantin line, regardless of design discount vantin 200mg on-line, were assessed for quality and assigned a rating of “good purchase vantin 100mg online,” “fair buy vantin 200mg visa,” or “poor”. Studies that have a fatal flaw were rated poor quality. A fatal flaw was the failure to meet combinations of criteria that may be related to indicate the presence of bias. An example would be inadequate procedures for allocation concealment combined with important differences between groups in prognostic factors at baseline and following randomization. Studies that meet all criteria were rated good quality; the remainders were rated fair quality. As the fair-quality category was broad, studies with this rating varied in their strengths and weaknesses: The results of some fair-quality studies were likely to be valid, while others were only possibly valid. A poor-quality trial was not valid; the results were at least as likely to reflect flaws in the study design as a true difference between the compared drugs. Criteria for assessing applicability (external validity) are also listed, although they were not used to determine study quality. Does the systematic review report a clear review question and clearly state inclusion and exclusion criteria for primary studies? A good-quality review focuses on a well-defined question or set of questions, which ideally refer to the inclusion/exclusion criteria by which decisions are made about whether to include or exclude primary studies. These criteria would relate to the four components of study design, indications (patient populations), interventions (drugs), and outcomes of interest. A good-quality review also includes details about the process of decision-making, that is, how many reviewers were involved, whether the studies were examined independently, and how disagreements between reviewers were resolved. Is there evidence of a substantial effort to find all relevant research? If details of electronic database searches and other identification strategies are given, the answer to this question usually is yes. Ideally, search terms, date restrictions, and language restrictions are presented. In addition, descriptions of hand-searches, attempts to identify unpublished material, and any contact with authors, industry, or research institutes should be provided. The appropriateness of the database(s) searched by the authors should also be considered. For example, if only MEDLINE is searched for a systematic review about health education, then it is unlikely that all relevant studies will be located. Is the validity of included studies adequately assessed? If the review systematically assesses the quality of primary studies, it should include an explanation of the basis for determining quality (for example, method of randomization, whether outcome assessment was blinded, whether analysis was on an intention-to-treat basis) and the process by which assessment is carried out (that is, how many reviewers are involved, whether the assessment is independent, and how discrepancies between reviewers are resolved). Authors Antihistamines Page 58 of 72 Final Report Update 2 Drug Effectiveness Review Project may have used either a published checklist or scale or one that they designed specifically for their review. Is sufficient detail of the individual studies presented? It is usually considered sufficient if a paper includes a table giving information on the design and results of individual studies or includes a narrative description of the studies. If relevant, the tables or text should include information on study design, sample size for each study group, patient characteristics, interventions, settings, outcome measures, follow-up, drop-out rate (withdrawals), effectiveness results, and adverse events. The authors should attempt to synthesize the results from individual studies. In all cases, there should be a narrative summary of results, which may or may not be accompanied by a quantitative summary (meta-analysis). For reviews that use a meta-analysis, heterogeneity between studies should be assessed using statistical techniques. If heterogeneity is present, the possible reasons (including chance) should be investigated. In addition, the individual evaluations should be weighted in some way (for example, according to sample size or according to inverse of the variance) so that studies that are thought to provide the most reliable data have greater impact on the summary statistic. Controlled Trials Assessment of Internal Validity 1. Was the assignment to the treatment groups really random? Adequate approaches to sequence generation: Computer-generated random numbers Random numbers tables Inferior approaches to sequence generation: Use of alternation, case record number, birth date, or day of week Not reported 2. Adequate approaches to concealment of randomization: Centralized or pharmacy-controlled randomization Serially-numbered identical containers On-site computer based system with a randomization sequence that is not readable until allocation Inferior approaches to concealment of randomization: Use of alternation, case record number, birth date, or day of week Open random numbers lists Serially numbered envelopes (even sealed opaque envelopes can be subject to manipulation) Antihistamines Page 59 of 72 Final Report Update 2 Drug Effectiveness Review Project Not reported 3. Were the groups similar at baseline in terms of prognostic factors? Were outcome assessors blinded to treatment allocation? Was the patient kept unaware of the treatment received? Did the article include an intention-to-treat analysis or provide the data needed to calculate it (that is, number assigned to each group, number of subjects who finished in each group, and their results)? Did the article report attrition, crossovers, adherence, and contamination? Is there important differential loss to follow-up or overall high loss to follow-up? Was the selection of patients for inclusion unbiased? Was there important differential loss to follow-up or overall high loss to follow-up? Was there a clear description of the techniques used to identify the events? Was there unbiased and accurate ascertainment of events (that is, by independent ascertainers using a validated ascertainment technique)? Were potential confounding variables and risk factors identified and examined using acceptable statistical techniques? Was the duration of follow-up reasonable for investigated events? Antihistamines Page 60 of 72 Final Report Update 2 Drug Effectiveness Review Project References 1. Center for Reviews and Dissemination, University of York, 2001. Current methods of the US Preventive Services Task Force: a review of the process. Antihistamines Page 61 of 72 Final Report Update 2 Drug Effectiveness Review Project Appendix D. Excluded studies in Update 2 The following full-text publications were considered for inclusion but failed to meet the criteria for this report. See previous versions of the report on the DERP website for studies excluded previously. Exclusion Excluded studies code # Head-to-head trials Day J, Briscoe M, Rafeiro E, et al. Comparative efficacy of cetirizine and fexofenadine for 6 seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit. Day JH, Briscoe MP, Rafeiro E, Hewlett D, Chapman D, Kramer B. Randomized double- 6 blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Loratadine provides early symptom control in seasonal 6 allergic rhinitis. Comparative study of sensory attributes of two 2 antihistamine nasal sprays: olopatadine 0. The effects of the nasal antihistamines 6 olopatadine and azelastine in nasal allergen provocation. Single center, randomized, double-blind, crossover study comparing the effects 4 of single-dose fexofenadine HCl 180 mg, cetirizine 10 mg, and placebo on cognitive performance in naval flight personnel [completed]. Five parallel groups, exploratory clinical trial to compare the efficacy of single dose 7 levocetirizine 2.
8 of 10 - Review by E. Temmy
Votes: 323 votes
Total customer reviews: 323